| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
LETC inhibits α-syn aggregation in transfected DH60.21 neuroblastoma cells with an EC50 of 66 nM[1].
|
|---|---|
| ln Vivo |
LETC (10 mg/kg; oral; 5 days per week; for 6 weeks) significantly reduced α-Syn-positive neurons in multiple brain regions, thereby rescuing the motor deficits of these mice in the open field. LETC does not improve the activity deficits of L62 mice in the home cage environment [1]. In α-Syn transgenic L62 mice, LETC accumulated in the brain after oral administration with a half-life of approximately 6 hours [1]. Pharmacokinetic parameters obtained after a single oral dose of LETC (15 mg/kg) in L62 mice. 1.19 parameter Plasma Brain Cmax (ng/mL) 155.0 1013.5 Tmax (h) 1.0 1.0
|
| Animal Protocol |
Animal/Disease Models:Full-length human α-Syn overexpressing Line 62 (L62) mice mice[1]
Doses: 10 mg/kg Route of Administration: Oral gavage; for 5 days per week; for 6 weeks Experimental Results: Significantly decreased α-Syn-positive neurons in multiple brain regions. |
| References |
| Molecular Formula |
C20H29CL2N3S
|
|---|---|
| Molecular Weight |
414.44
|
| Appearance |
Light blue to blue solid powder
|
| SMILES |
CCN(CC)C1=CC=C2C(SC3=C(N2)C=CC(N(CC)CC)=C3)=C1.Cl.Cl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~241.3 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4129 mL | 12.0645 mL | 24.1289 mL | |
| 5 mM | 0.4826 mL | 2.4129 mL | 4.8258 mL | |
| 10 mM | 0.2413 mL | 1.2064 mL | 2.4129 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
